Black Rose Industries revenue up 4.3% in FY26 to ₹323 crore; PAT rises 7%
Black Rose Industries reported FY26 consolidated revenue of ₹323.01 crore (+4.3% YoY) and PAT of ₹22.42 crore (+7.1% YoY). The Board recommended a ₹1.25 per share final dividend. Manufacturing volumes for acrylamide and NMA drove growth, while the distribution segment faced temporary headwinds.

*this image is generated using AI for illustrative purposes only.
Black Rose Industries has released its annual report for the financial year ended March 31, 2026, reporting steady growth across key financial metrics despite a challenging operating environment. The company recorded consolidated revenue from operations of ₹323.01 crore, a 4.3% increase from the previous year. Consolidated profit after tax (PAT) stood at ₹22.42 crore, marking a 7.1% year-on-year growth.
Financial Performance
The company's EBITDA margin expanded by 9.1% year-on-year to 10.97%, with EBITDA reaching ₹35.44 crore. The net profit margin was reported at 6.94%. On a standalone basis, revenue from operations decreased by 4.25% to ₹323.01 crore (₹32,301.40 lakh), while standalone PAT fell to ₹22.50 crore (₹2,249.61 lakh) from ₹26.59 crore in the prior year.
| Metric: | FY26 | FY25 | YoY Change |
|---|---|---|---|
| Revenue (Consolidated): | ₹323.01 crore | ₹310.00 crore* | +4.3% |
| PAT (Consolidated): | ₹22.42 crore | ₹20.94 crore* | +7.1% |
| EBITDA Margin: | 10.97% | 10.06%* | +9.1% |
| Net Profit Margin: | 6.94% | 6.44%* | +7.8% |
Note: Previous year figures derived from disclosed growth percentages where absolute values were not explicitly stated in the summary highlights.
Operational Highlights
The manufacturing business remained the primary driver of profitability. Acrylamide liquid volumes registered healthy growth driven by strong domestic demand and export market acceptance. The N-Methylol Acrylamide (NMA) business delivered an outstanding performance, with sales volumes nearly doubling over the previous year due to higher offtakes from key customers and new additions. The company also advanced its polyacrylamide (PAM) project to the piloting stage, signaling progress in downstream product development.
The distribution business faced subdued export demand during parts of the year due to global uncertainty but saw improvement towards the latter part of FY26. The company discontinued its polyacrylamide liquid business and exited the ceramic binder segment in Morbi to focus on areas with stronger long-term potential.
Dividend and AGM Details
The Board of Directors, in its meeting held on May 13, 2026, recommended a final dividend of ₹1.25 per equity share of face value ₹1 each for FY26. This recommendation is subject to approval by shareholders at the 36th Annual General Meeting (AGM) scheduled for Wednesday, September 9, 2026, at 2:00 pm via Video Conferencing or Other Audio Visual Means (VC/OAVM).
Key dates for shareholders include:
- Record Date: September 2, 2026
- AGM Date: September 9, 2026
- Book Closure Period: September 3, 2026 to September 9, 2026
Corporate Governance and Strategy
Mr. Anup Jatia, Non-Executive Director, retires by rotation and offers himself for re-appointment. The Board also seeks ratification of remuneration for M/s. Poddar & Co., Cost Accountants, for the financial year ending March 31, 2027.
The company emphasized its strategy of "Deepening Chemistry, Broadening Horizons," focusing on expanding manufacturing capabilities, widening customer reach, and reinforcing its position across the chemical value chain. Capital employed increased by 3.64% to ₹166.50 crore, while net worth rose by 10.90% to ₹169.28 crore, reflecting retained profits.
Historical Stock Returns for Black Rose Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.00% | +8.68% | +16.06% | +36.83% | +36.83% | +36.83% |
How will the successful piloting of the polyacrylamide (PAM) project impact Black Rose Industries' revenue mix and margin profile in FY27?
What specific strategies is the company deploying to mitigate risks from subdued global export demand in its distribution business?
Will the exit from the ceramic binder segment and polyacrylamide liquid business free up sufficient capital to accelerate downstream product development?


































